CME webinar: Pediatric Asthma Management Guidelines

Jul. 2022Education/Webinars
"Please join us for a live, CME-accredited webinar Wednesday, Aug. 24, from noon to 1 p.m. The presentation will include an overview of the latest 2020 Pediatric Asthma Management Guidelines, including:

  • The use of as-needed courses of inhaled corticosteroids in the management of mild persistent asthma.
  • The use of single-inhaler maintenance and reliever therapy (SMART) in moderate persistent asthma.
  • Strategies and potential barriers to the implementation of new asthma management guidelines.
  • Sharing UPMC Health Plan asthma resources.


Presenters:

  • Erick Forno, MD, MPH, ATSF, Director, CHP Pediatric Asthma Center Division of Pediatric Pulmonary Medicine at UPMC Children’s Hospital of Pittsburgh/University of Pittsburgh School of Medicine
  • Deborah Moss, MD, MPH, FAAP, Professor of Pediatrics, University of Pittsburgh Children’s Hospital of Pittsburgh of UPMC Division of General Academic Pediatrics; Pediatric Medical Director, UPMC for You; and Medical Director, UPMC for Kids
  • Erin McConnell, PharmD, Program Manager, Pharmacy Quality, UPMC Health Plan


Register now at upmchp.us/asthma. This webinar will be recorded.

You may earn continuing medical education (CME) credits for attending this webinar.*

*This activity is approved for AMA PRA Category 1 Credit™ and ANCC. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Provider is responsible for verifying CME eligibility.
"

Recent Announcements

October 2025 UPMC for You and UPMC Community HealthChoices formulary update

Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.
Oct. 2025Pharmacy Updates

Voluntary nationwide recall: Ocaliva (Intercept – September)

Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).
Oct. 2025Pharmacy Updates

HelpScript service helps patients enroll in manufacturer copay assistance programs

End-to-end provider support helps ensure a smooth submission process
Oct. 2025Important Notices